News

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...
AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...
CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology ...